- Home
- MCI vs CELC Comparison
MCI vs CELC Comparison
Compare MCI & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCI
- CELC
- Stock Information
- Founded
- MCI 1971
- CELC 2011
- Country
- MCI United States
- CELC United States
- Employees
- MCI N/A
- CELC N/A
- Industry
- MCI Trusts Except Educational Religious and Charitable
- CELC Medical Specialities
- Sector
- MCI Finance
- CELC Health Care
- Exchange
- MCI Nasdaq
- CELC Nasdaq
- Market Cap
- MCI 418.4M
- CELC 440.0M
- IPO Year
- MCI N/A
- CELC 2017
- Fundamental
- Price
- MCI $21.16
- CELC $11.60
- Analyst Decision
- MCI
- CELC Strong Buy
- Analyst Count
- MCI 0
- CELC 5
- Target Price
- MCI N/A
- CELC $30.80
- AVG Volume (30 Days)
- MCI 40.4K
- CELC 140.7K
- Earning Date
- MCI 01-01-0001
- CELC 08-13-2025
- Dividend Yield
- MCI 8.46%
- CELC N/A
- EPS Growth
- MCI N/A
- CELC N/A
- EPS
- MCI 1.82
- CELC N/A
- Revenue
- MCI N/A
- CELC N/A
- Revenue This Year
- MCI N/A
- CELC N/A
- Revenue Next Year
- MCI N/A
- CELC N/A
- P/E Ratio
- MCI $9.88
- CELC N/A
- Revenue Growth
- MCI N/A
- CELC N/A
- 52 Week Low
- MCI $12.96
- CELC $7.58
- 52 Week High
- MCI $19.24
- CELC $19.77
- Technical
- Relative Strength Index (RSI)
- MCI 62.18
- CELC 49.88
- Support Level
- MCI $20.52
- CELC $11.85
- Resistance Level
- MCI $21.57
- CELC $13.40
- Average True Range (ATR)
- MCI 0.62
- CELC 0.70
- MACD
- MCI 0.18
- CELC -0.09
- Stochastic Oscillator
- MCI 82.33
- CELC 35.83
About MCI Barings Corporate Investors
Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations, including bank loans and mezzanine debt instruments. The Trust typically purchases these investments, which are not publicly tradable, directly from their issuers in private placement transactions, and the investments are typically made to small or middle market companies.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.